What the trial was testing
The FRIDA enrolled 336 patients with stroke. The study was sponsored by Supergene, LLC and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
50% of patients treated with staphylokinase had good recovery, versus 40% with standard treatment.
The Lancet. Neurology · 2021 · NCT03151993
These findings — that half of stroke patients treated with staphylokinase recovered to independence at 3 months — were published in the The Lancet. Neurology and represent the headline result of the study.
Researchers tracked outcomes across 336 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with stroke, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Staphylokinase is not yet FDA-approved in the United States. This large trial in Russia showed it worked as well as the current standard clot-buster, alteplase, and may cause fewer serious side effects. If you or a loved one has a stroke, call 911 immediately — alteplase is widely available and proven to save lives when given quickly.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open stroke trials
Establishing Mechanical Thrombectomy at a Limited-volume Stroke Center - Effects on Patient Morbidity and Mortality
The regional health authorities of South-East Norway has commissioned Sørlandet Hospital (SSHF), Norway to establish mechanical thrombectomy in large-vessel occlusion stroke. SSHF is a limited volume stroke center, and introduction of thrombectomy may impose quality challenges. Therefore the implementation will be guided by a simulation based quality assurance program. In this study, we will monitor timelines, technical and clinical outcomes, including adverse events.
Digital Technology-Informed Stroke Rehabilitation
The goal of this study is to determine the effects of lab and home-based technology guidance during movement training post-stroke. The study will compare movement training informed by lab-based technology to training delivered with technology at home. The main questions it aims to answer are: * How well do lab and home-based technologies help individuals post-stroke improve their movement patterns? * Is there a difference in improvement between the in-lab and at-home training groups? * Which technologies lead to the most improvement?